172 related articles for article (PubMed ID: 23883824)
1. Risk of cancer after lumbar fusion surgery with recombinant human bone morphogenic protein-2 (rh-BMP-2).
Cooper GS; Kou TD
Spine (Phila Pa 1976); 2013 Oct; 38(21):1862-8. PubMed ID: 23883824
[TBL] [Abstract][Full Text] [Related]
2. The Risk of Cancer With the Use of Recombinant Human Bone Morphogenetic Protein in Spine Fusion.
Dettori JR; Chapman JR; DeVine JG; McGuire RA; Norvell DC; Weiss NS
Spine (Phila Pa 1976); 2016 Aug; 41(16):1317-1324. PubMed ID: 27261568
[TBL] [Abstract][Full Text] [Related]
3. Routine use of recombinant human bone morphogenetic protein-2 in posterior fusions of the pediatric spine and incidence of cancer.
Sayama C; Willsey M; Chintagumpala M; Brayton A; Briceño V; Ryan SL; Luerssen TG; Hwang SW; Jea A
J Neurosurg Pediatr; 2015 Jul; 16(1):4-13. PubMed ID: 25860984
[TBL] [Abstract][Full Text] [Related]
4. Comparison of transforaminal lumbar interbody fusion outcomes in patients receiving rhBMP-2 versus autograft.
Khan TR; Pearce KR; McAnany SJ; Peters CM; Gupta MC; Zebala LP
Spine J; 2018 Mar; 18(3):439-446. PubMed ID: 28822825
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk after use of recombinant bone morphogenetic protein-2 for spinal arthrodesis.
Carragee EJ; Chu G; Rohatgi R; Hurwitz EL; Weiner BK; Yoon ST; Comer G; Kopjar B
J Bone Joint Surg Am; 2013 Sep; 95(17):1537-45. PubMed ID: 24005193
[TBL] [Abstract][Full Text] [Related]
6. Bone Morphogenetic Proteins in Spinal Surgery: What Is the Fusion Rate and Do They Cause Cancer?
Malham GM; Giles GG; Milne RL; Blecher CM; Brazenor GA
Spine (Phila Pa 1976); 2015 Nov; 40(22):1737-42. PubMed ID: 26730525
[TBL] [Abstract][Full Text] [Related]
7. Recombinant human bone morphogenetic protein-2 and pancreatic cancer: a retrospective cohort study.
Mines D; Gu Y; Kou TD; Cooper GS
Pharmacoepidemiol Drug Saf; 2011 Feb; 20(2):111-8. PubMed ID: 21254281
[TBL] [Abstract][Full Text] [Related]
8. Blood serum antibody analysis and long-term follow-up of patients treated with recombinant human bone morphogenetic protein-2 in the lumbar spine.
Burkus JK; Gornet MF; Glassman SD; Slosar PJ; Rosner MK; Deckey JE; Nowak J; Hatcher BM
Spine (Phila Pa 1976); 2011 Dec; 36(25):2158-67. PubMed ID: 21325990
[TBL] [Abstract][Full Text] [Related]
9. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679
[TBL] [Abstract][Full Text] [Related]
10. Retrograde ejaculation following single-level anterior lumbar surgery with or without recombinant human bone morphogenetic protein-2 in 5 randomized controlled trials: clinical article.
Burkus JK; Dryer RF; Peloza JH
J Neurosurg Spine; 2013 Feb; 18(2):112-21. PubMed ID: 23199378
[TBL] [Abstract][Full Text] [Related]
11. RhBMP-2-induced radiculitis in patients undergoing transforaminal lumbar interbody fusion: relationship to dose.
Villavicencio AT; Burneikiene S
Spine J; 2016 Oct; 16(10):1208-1213. PubMed ID: 27343729
[TBL] [Abstract][Full Text] [Related]
12. A 24-month retrospective update: follow-up hospitalization charges and readmissions in US lumbar fusion surgeries using a cellular bone allograft (CBA) versus recombinant human bone morphogenetic protein-2 (rhBMP-2).
Wetzell B; McLean JB; Dorsch K; Moore MA
J Orthop Surg Res; 2021 Nov; 16(1):680. PubMed ID: 34794470
[TBL] [Abstract][Full Text] [Related]
13. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
Hoffmann MF; Jones CB; Sietsema DL
Spine J; 2013 Oct; 13(10):1244-52. PubMed ID: 23973099
[TBL] [Abstract][Full Text] [Related]
14. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 2: BMP dosage-related complications and long-term outcomes in 509 patients.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1137-45. PubMed ID: 23354111
[TBL] [Abstract][Full Text] [Related]
15. Bone morphogenetic protein use in spine surgery-complications and outcomes: a systematic review.
Faundez A; Tournier C; Garcia M; Aunoble S; Le Huec JC
Int Orthop; 2016 Jun; 40(6):1309-19. PubMed ID: 26961193
[TBL] [Abstract][Full Text] [Related]
16. Adverse Events With the Use of rhBMP-2 in Thoracolumbar and Lumbar Spine Fusions: A 9-Year Institutional Analysis.
Lubelski D; Abdullah KG; Steinmetz MP; Alvin MD; Nowacki AS; Chakka S; Benzel EC; Mroz TE
J Spinal Disord Tech; 2015 Jun; 28(5):E277-83. PubMed ID: 23429306
[TBL] [Abstract][Full Text] [Related]
17. RhBMP-2 use in lumbar fusion surgery is associated with transient immediate post-operative leg pain.
Rowan FE; O'Malley N; Poynton A
Eur Spine J; 2012 Jul; 21(7):1331-7. PubMed ID: 22167451
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion.
Chen NF; Smith ZA; Stiner E; Armin S; Sheikh H; Khoo LT
J Neurosurg Spine; 2010 Jan; 12(1):40-6. PubMed ID: 20043763
[TBL] [Abstract][Full Text] [Related]
19. Quantitative study of parathyroid hormone (1-34) and bone morphogenetic protein-2 on spinal fusion outcomes in a rabbit model of lumbar dorsolateral intertransverse process arthrodesis.
Lina IA; Puvanesarajah V; Liauw JA; Lo SF; Santiago-Dieppa DR; Hwang L; Mao A; Bydon A; Wolinsky JP; Sciubba DM; Gokaslan Z; Holmes C; Witham TF
Spine (Phila Pa 1976); 2014 Mar; 39(5):347-55. PubMed ID: 24365898
[TBL] [Abstract][Full Text] [Related]
20. Longer follow-up continues to reveal no increased risk of cancer with the use of recombinant human bone morphogenetic protein in spine fusion.
Dettori JR; Chapman JR; DeVine JG; McGuire RA; Junge MR; Norvell DC
Spine J; 2019 Oct; 19(10):1640-1647. PubMed ID: 31108234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
